Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

A worldwide perspective of atypical pathogens in community-acquired pneumonia.

Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, Blasi F, Fernandez P, File TM Jr, Rello J, Menendez R, Marzoratti L, Luna CM, Ramirez JA; Community-Acquired Pneumonia Organization (CAPO) Investigators.

Am J Respir Crit Care Med. 2007 May 15;175(10):1086-93. Epub 2007 Mar 1.

PMID:
17332485
2.

Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia.

Lui G, Ip M, Lee N, Rainer TH, Man SY, Cockram CS, Antonio GE, Ng MH, Chan MH, Chau SS, Mak P, Chan PK, Ahuja AT, Sung JJ, Hui DS.

Respirology. 2009 Nov;14(8):1098-105. doi: 10.1111/j.1440-1843.2009.01637.x. Epub 2009 Oct 5.

PMID:
19818051
3.

Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.

Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L, Leibovici L.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004418. doi: 10.1002/14651858.CD004418.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;9:CD004418.

PMID:
18254049
4.

Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.

Shefet D, Robenshtock E, Paul M, Leibovici L.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004418. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD004418.

PMID:
15846713
5.

Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study.

Arnold FW, Wiemken TL, Peyrani P, Ramirez JA, Brock GN; CAPO authors.

Respir Med. 2013 Jul;107(7):1101-11. doi: 10.1016/j.rmed.2013.04.003. Epub 2013 May 6.

6.

Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.

Arnold FW, LaJoie AS, Brock GN, Peyrani P, Rello J, Menéndez R, Lopardo G, Torres A, Rossi P, Ramirez JA; Community-Acquired Pneumonia Organization (CAPO) Investigators.

Arch Intern Med. 2009 Sep 14;169(16):1515-24. doi: 10.1001/archinternmed.2009.265.

PMID:
19752410
7.

Improvement in clinical and economic outcomes with empiric antibiotic therapy covering atypical pathogens for community-acquired pneumonia patients: a multicenter cohort study.

Ye X, Ma J, Hu B, Gao X, He L, Shen W, Weng L, Cai L, Huang Y, Hu Z, Xu J, Zhao L, Huang M, Cui X, Tu C.

Int J Infect Dis. 2015 Nov;40:102-7. doi: 10.1016/j.ijid.2015.03.012. Epub 2015 Mar 24.

8.

Appropriate outpatient macrolide use in community-acquired pneumonia.

Gotfried MH.

J Am Acad Nurse Pract. 2004 Apr;16(4):146, 148, 150 passim. Review.

PMID:
15137473
9.

Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.

Piso RJ, Arnold C, Bassetti S.

Swiss Med Wkly. 2013 Sep 19;143:w13870. doi: 10.4414/smw.2013.13870.

10.

Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

Eliakim-Raz N, Robenshtok E, Shefet D, Gafter-Gvili A, Vidal L, Paul M, Leibovici L.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004418. doi: 10.1002/14651858.CD004418.pub4. Review.

PMID:
22972070
11.

A prospective comparison of nursing- and healthcare-associated pneumonia (NHCAP) with community-acquired pneumonia (CAP).

Fukuyama H, Yamashiro S, Tamaki H, Kishaba T.

J Infect Chemother. 2013 Aug;19(4):719-26. doi: 10.1007/s10156-013-0557-1. Epub 2013 Jan 25.

PMID:
23354936
12.
13.

How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.

Oosterheert JJ, Bonten MJ, Hak E, Schneider MM, Hoepelman IM.

J Antimicrob Chemother. 2003 Oct;52(4):555-63. Epub 2003 Sep 12. Review.

PMID:
12972448
14.

Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials.

Shefet D, Robenshtok E, Paul M, Leibovici L.

Arch Intern Med. 2005 Sep 26;165(17):1992-2000. Review.

PMID:
16186469
15.

The emerging role of atypical pathogens in community-acquired pneumonia.

Gleason PP.

Pharmacotherapy. 2002 Jan;22(1 Pt 2):2S-11S; discussion 30S-32S.

PMID:
11791627
16.

Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.

Frei CR, Attridge RT, Mortensen EM, Restrepo MI, Yu Y, Oramasionwu CU, Ruiz JL, Burgess DS.

Clin Ther. 2010 Feb;32(2):293-9. doi: 10.1016/j.clinthera.2010.02.006.

PMID:
20206787
17.
18.

Community acquired pneumonia in diabetic and non-diabetic hospitalized patients: presentation, causative pathogens and outcome.

Saibal MA, Rahman SH, Nishat L, Sikder NH, Begum SA, Islam MJ, Uddin KN.

Bangladesh Med Res Counc Bull. 2012 Dec;38(3):98-103.

PMID:
23540185
19.

A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.

Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.

Curr Med Res Opin. 2008 Mar;24(3):895-906. doi: 10.1185/030079908X273408.

PMID:
18419876

Supplemental Content

Support Center